Rossney Angela S, Shore Anna C, Morgan Pamela M, Fitzgibbon Margaret M, O'Connell Brian, Coleman David C
National MRSA Reference Laboratory, St. James's Hospital, James's St., Dublin 8, Ireland.
J Clin Microbiol. 2007 Aug;45(8):2554-63. doi: 10.1128/JCM.00245-07. Epub 2007 Jun 20.
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) carrying pvl is an emerging problem worldwide. CA-MRSA tends to harbor staphylococcal cassette chromosome mec type IV (SCCmec IV), to be non-multiantibiotic resistant, and to have different genotypes from the local hospital-acquired MRSA (HA-MRSA). However, in Ireland, 80% of HA-MRSA isolates have the non-multiantibiotic-resistant genotype ST22-MRSA-IV. This study investigated MRSA isolates from Ireland (CA-MRSA, health care-associated MRSA, and HA-MRSA) for the carriage of pvl and determined the genotypic characteristics of all pvl-positive isolates identified. All 1,389 MRSA isolates were investigated by antibiogram-resistogram typing and SmaI DNA macrorestriction analysis. pvl-positive isolates were further characterized by multilocus sequence typing and SCCmec, agr, and toxin gene typing. Twenty-five (1.8%) MRSA isolates belonging to six genotypes (ST30, ST8, ST22, ST80, ST5, and ST154) harbored pvl. Nineteen of these (76%) were CA-MRSA isolates, but a prospective study of MRSA isolates from 401 patients showed that only 6.7% (2/30) of patients with CA-MRSA yielded pvl-positive isolates. Thus, pvl cannot be used as a sole marker for CA-MRSA. Fifty-two percent of pvl-positive MRSA isolates were recovered from patients with skin and soft tissue infections; thirty-six percent were from patients of non-Irish ethnic origin, reflecting the increasing heterogeneity of the Irish population due to immigration. All 25 pvl-positive isolates carried SCCmec IV; 14 (56%) harbored SCCmec IV.1 or IV.3, and the remaining 11 isolates could not be subtyped. This study demonstrates that pvl is not a reliable marker for CA-MRSA in Ireland and reveals the emergence and importation of diverse genotypes of pvl-positive MRSA in Ireland.
携带杀白细胞素(pvl)的社区获得性耐甲氧西林金黄色葡萄球菌(CA-MRSA)是一个在全球范围内逐渐凸显的问题。CA-MRSA往往携带IV型葡萄球菌盒式染色体mec(SCCmec IV),对多种抗生素不耐药,并且具有与当地医院获得性耐甲氧西林金黄色葡萄球菌(HA-MRSA)不同的基因型。然而,在爱尔兰,80%的HA-MRSA分离株具有对多种抗生素不耐药的基因型ST22-MRSA-IV。本研究调查了来自爱尔兰的耐甲氧西林金黄色葡萄球菌分离株(CA-MRSA、医疗保健相关耐甲氧西林金黄色葡萄球菌和HA-MRSA)是否携带pvl,并确定了所有鉴定出的pvl阳性分离株的基因型特征。对所有1389株耐甲氧西林金黄色葡萄球菌分离株进行了抗菌谱-耐药谱分型和SmaI DNA宏观限制性分析。pvl阳性分离株通过多位点序列分型以及SCCmec、agr和毒素基因分型进行进一步鉴定。25株(1.8%)属于6种基因型(ST30、ST8、ST22、ST80、ST5和ST154)的耐甲氧西林金黄色葡萄球菌分离株携带pvl。其中19株(76%)为CA-MRSA分离株,但一项对401例患者的耐甲氧西林金黄色葡萄球菌分离株的前瞻性研究表明,CA-MRSA患者中只有6.7%(2/30)产生pvl阳性分离株。因此,pvl不能用作CA-MRSA的唯一标志物。52%的pvl阳性耐甲氧西林金黄色葡萄球菌分离株从皮肤和软组织感染患者中分离得到;36%来自非爱尔兰族裔患者,这反映出由于移民,爱尔兰人口的异质性在增加。所有25株pvl阳性分离株均携带SCCmec IV;14株(56%)携带SCCmec IV.1或IV.3,其余11株分离株无法进行亚型分类。本研究表明,在爱尔兰,pvl不是CA-MRSA的可靠标志物,并揭示了爱尔兰pvl阳性耐甲氧西林金黄色葡萄球菌不同基因型的出现和输入情况。